Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29486327 | 1.00 | EGFR (0.34) | EGFR | |
| SCHEMBL29486324 | 1.00 | EGFR (0.34) | EGFR | |
| SCHEMBL28662975 | 0.82 | EGFR (0.33) | EGFR | |
| SCHEMBL2041949 | 0.76 | NFKB1 (0.39) | EGFR | |
| SCHEMBL25850566 | 0.75 | EGFR (0.48) | EGFR | |
| SCHEMBL17917476 | 0.71 | IMPDH2 (0.44) | EGFR | |
| SCHEMBL1056993 | 0.71 | EGFR (0.52) | EGFR | |
| SCHEMBL30432091 | 0.71 | EGFR (0.47) | EGFR | |
| SCHEMBL1096307 | 0.71 | EGFR (0.47) | EGFR | |
| SCHEMBL31244437 | 0.70 | HTR2A (0.38) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600731-B2 | Isoxazolo[5,4-H]quinazoline compounds as protein kinase inhibitors | Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. (CN) | 2026-04-14 | — | — | US | disclosed |
| US-20220363690-A1 | ISOXAZOLO[5,4-H]QUINAZOLINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. (CN) | 2022-11-17 | — | — | US | disclosed |
| WO-2021043190-A1 | ISOXAZOLO[5,4-H]QUINAZOLINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | 成都赛诺希亚生物科技有限公司 | 2021-03-11 | — | — | WO | disclosed |
| WO-2021043190-A1 | ISOXAZOLO[5,4-H]QUINAZOLINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | 成都赛诺希亚生物科技有限公司 | 2021-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363690-A1 | ISOXAZOLO[5,4-H]QUINAZOLINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | CDK2, CDKL1, CDK7 | EGFR 2107/4885 |
| US-12600731-B2 | Isoxazolo[5,4-H]quinazoline compounds as protein kinase inhibitors | CCNO, CDK7, CDK6 | EGFR 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.